To r

egis

ter

visi

t go

top

er.c

om/g

o/W

LC19

TR

I

goto

per

.com

/go/

WLC

19T

RI

Vis

it u

s at

Phys

icia

ns’ E

duca

tion

Reso

urce

®, L

LC2

Cla

rke

Driv

e, S

uite

110

Cra

nbur

y, N

J 085

12

JAN

UA

RY 2

5-27

, 201

9 ED

EN R

OC

MIA

MI B

EAC

H •

MIA

MI,

FL

Com

bine

d w

ith t

he M

iam

i Lun

g C

ance

r C

onfe

renc

e®

JAN

UA

RY 2

5-27

, 201

9ED

EN R

OC

MIA

MI B

EAC

H

MIA

MI,

FLC

ombi

ned

with

the

M

iam

i Lun

g C

ance

r C

onfe

renc

e®

Meeting Overview

Benefits of Attending This Year’s Meeting:

We are excited to combine the historic Winter Lung Cancer Conference™ with the Miami Lung Cancer Conference® to offer you a world-class continuing medical education event for the treatment of patients with lung cancer. This year’s meeting will continue the traditional educational format of the Winter Lung Cancer Conference™ and incorporate the dynamic Medical Crossfire® exchanges that Miami Lung is best known for.

• Network with expert faculty and your colleagues

• Hear about practice-changing data in lung cancers

• Unravel the complexity of emerging immunotherapy-based regimens

• Learn about optimizing the sequencing of targeted agents

• Get personalized advice from experts at Meet-the-Professor breakout sessions

Registration

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

ADVANCED ON-SITE

Physicians $75 $125

Fellows* $60 $99

Nurses, PAs, Other HCPs $50 $75

Industry** $1099 $1399

• N

etw

ork

with

the

Expe

rt F

acul

ty a

nd Y

our C

olle

ague

s•

Inte

grat

e Re

cent

Dat

a in

to Y

our P

ract

ice!

Prog

ram

Co-

Chai

rsRo

gerio

C. L

ilenb

aum

, MD

Prof

esso

r of M

edic

ine

in M

edic

al O

ncol

ogy

Chi

ef M

edic

al O

ffice

r of S

milo

w C

ance

r Hos

pita

l –

Yal

e N

ew H

aven

Hea

lth

New

Hav

en, C

T

Mar

k A

. Soc

insk

i, M

D

Exec

utiv

e M

edic

al D

irect

or

Flor

ida

Hos

pita

l Can

cer I

nstit

ute

Orla

ndo,

FL

Hea

ther

A. W

akel

ee, M

D

Prof

esso

r, M

edic

ine

(Onc

olog

y)

Stan

ford

Uni

vers

ity M

edic

al C

ente

r St

anfo

rd, C

A

Julie

Bra

hmer

, MD

In

terim

Dire

ctor

, Sid

ney

Kim

mel

Com

preh

ensiv

e

Can

cer C

ente

r Pr

ofes

sor o

f Onc

olog

y Jo

hns H

opki

ns S

idne

y Ki

mm

el C

ompr

ehen

sive

C

ance

r Cen

ter

Balti

mor

e, M

D

Earn

a

max

imum

of

11.

0 A

MA

PR

A C

ateg

ory

1 C

redi

ts™

.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 11.0 Contact Hours.

TWO WAYS TO REGISTER

Online Call

gotoper.com /go/WLC19TRI

For any other question email us at: info@gotoper.com

609-378-3701

or

Agenda

Friday, January 256:30 pm Welcome Reception7:15 pm Keynote Address7:45 pm Moderated Q &A Session8:00 pm Closing Remarks and Adjourn

Saturday, January 267:45 am Welcome, Introductions, and Presession SurveyModule 1: Oncogenic Drivers: EGFR and ALK8:00 am First-Line Therapy for Patients With EGFR Mutation-Positive NSCLC8:15 am Moderated Q&A Session8:20 am Third-Generation EGFR Inhibitors: Mechanisms of Resistance and

Treatment Options8:35 am Moderated Q&A Session8:40 am Intersection of EGFR Mutations and Immunotherapy: How to Bring

Benefit to Patients8:55 am Moderated Q&A Session9:00 am ALK-Rearranged NSCLC: Choosing Therapy Through Multiple Lines of

Treatment9:15 am Moderated Q&A Session9:20 am Postsession Survey9:25 am Panel Discussion9:35 am BREAKModule 2: Oncogenic Drivers: The Growing Cohort10:00 am Postsession Survey10:05 am Approaches for ROS1 and BRAF: Current and Emerging Options10:20 am Moderated Q&A Session10:25 am Targeted Therapy for Emerging Oncogenic Drivers (Including RET, MET,

HER2)10:40 am Moderated Q&A Session

10:45 am Managing CNS Disease in Oncogene-Driven NSCLC11:00 am Moderated Q&A Session11:05 am Testing for Acquired Resistance: When and How?11:20 am Moderated Q&A Session11:25 am Panel DiscussionModule 3: Immunotherapy: Practical Applications - 111:35 am Choosing First-Line Immunotherapy: Single-Agent or Combination in

Nonsquamous NSCLC11:50 am Moderated Q&A Session11:55 am Choosing First-Line Immunotherapy: Single-Agent or Combination in

Squamous NSCLC12:10 pm Moderated Q&A Session12:15 pm Mitigating and Managing Resistance to Immunotherapy12:30 pm Moderated Q&A Session12:35 pm Pushing the Envelope: Expanding Real-World Eligibility for Immunotherapy12:50 pm Moderated Q&A Session12:55 pm Postsession Survey1:00 pm Panel Discussion1:10 pm LUNCHModule 4: Surgery, Radiation Therapy, and Other Issues2:20 pm Presession Survey2:25 pm Current Topics in Lung Cancer Surgery2:40 pm Moderated Q&A Session2:45 pm Best Practices for Radiation Therapy in Lung Cancer3:00 pm Moderated Q&A Session3:05 pm Managing Patients With Oligometastatic Disease3:20 pm Moderated Q&A Session3:25 pm Immunotherapy and Targeted Agents in the (Neo)Adjuvant Setting3:40 pm Moderated Q&A Session3:45 pm Postsession Survey3:50 pm Panel Discussion4:00 pm Closing Remarks and Adjourn

Sunday, January 27Module 5: Practice of Oncology7:45 am Welcome, Introductions, and Presession Survey8:00 am Integrating Palliative Care in the Management of Patients With Lung

Cancer8:15 am Moderated Q&A Session8:20 am Preparing for Alternative Reimbursement Models8:35 am Moderated Q&A Session8:40 am Panel DiscussionModule 6: Next Steps for Thoracic Malignancies8:50 am Immunotherapy Beyond PD-(L)1/CTLA-49:05 am Moderated Q&A Session9:10 am Do We Have New Standards of Care for Patients With SCLC?9:25 am Moderated Q&A Session9:30 am Emerging Approaches for Mesothelioma9:45 am Moderated Q&A Session9:50 am Postsession Survey9:55 am Panel Discussion10:05 am BREAKModule 7: Immunotherapy: Practical Applications - 210:30 am Presession Survey10:35 am Integration of Immunotherapy in Unresectable Stage III NSCLC10:50 am Moderated Q&A Session10:55 am Management of Immune-Related Adverse Events11:10 am Moderated Q&A Session11:15 am With Immunotherapy Plus Chemotherapy, What Are the Roles of PD-L1

and TMB?11:30 am Moderated Q&A Session11:35 am Medical Crossfire®: For Patients With Stage IV NSCLC and PD-L1 ≥50%,

Is the Standard of Care Immunotherapy Alone or Immunotherapy Plus Chemotherapy?

11:50 am Moderated Q&A Session11:55 am Postsession Survey12:00 pm Panel Discussion12:15 pm Closing Remarks and Adjourn

Agenda accurate at time of printing

For more information and to register visit gotoper.com/go/WLC19TRI

FacultyChristina Baik MD, MPHUniversity of WashingtonSeattle, WA

Roy H. Decker, MD, PhDYale University School of MedicineNew Haven, CT

Edward B. Garon, MD, MS David Geffen School of Medicine at UCLALos Angeles, CA

Sarah B. Goldberg, MD, MPH Yale Cancer CenterNew Haven, CT

Leora Horn, MDClinical Director, Thoracic Oncology ProgramNashville, TN

Jennifer Kapo, MDYale University School of Medicine New Haven, CT

Gilberto de Lima Lopes Junior, MD, MBA, FAMSSylvester Comprehensive Cancer Center at the University of Miami and the Miller School of MedicineMiami, FL

Jarushka Naidoo, MB BCHJohns Hopkins UniversityBaltimore, MD

Suresh S. Ramalingam, MDEmory University School of MedicineAtlanta, GA

Sukhmani K. Padda MDStanford University Medical CenterStanford, CA

Rathi Pillai, MDEmory UniversityAtlanta, GA

Gregory Riely, MD, PhD Memorial Sloan-Kettering Cancer CenterNew York, NY

Liza C. Villaruz, MDUPMC Hillman Cancer CenterPittsburgh, PA